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Oxidative metabolism drives inflammation-induced
platinum resistance in human ovarian cancer
DS Matassa1,8, MR Amoroso1,8, H Lu2, R Avolio1, D Arzeni1, C Procaccini3, D Faicchia4, F Maddalena5, V Simeon5, I Agliarulo1, E Zanini2,
C Mazzoccoli5, C Recchi2, E Stronach6, G Marone4, H Gabra6, G Matarese1, M Landriscina*,5,7 and F Esposito*,1
Tumour cells have long been considered defective in mitochondrial respiration and mostly dependent on glycolytic metabolism.
However, this assumption is currently challenged by several lines of evidence in a growing number of tumours. Ovarian cancer
(OC) is one of the most lethal cancers worldwide, but it continues to be a poorly understood disease and its metabolic features are
far to be elucidated. In this context, we investigated the role of tumour necrosis factor receptor-associated protein 1 (TRAP1),
which is found upregulated in several cancer types and is a key modulator of tumour cell metabolism. Surprisingly, we found that
TRAP1 expression inversely correlated with grade, stage and lower survival in a large cohort of OC patients. Accordingly, TRAP1
silencing induced resistance to cisplatin, resistant cells showed increased oxidative metabolism compared with their sensitive
counterpart, and the bioenergetics cellular index of higher grade tumours indicated increased mitochondrial respiration. Strikingly,
cisplatin resistance was reversible upon pharmacological inhibition of mitochondrial oxidative phosphorylation by metformin/
oligomycin. At molecular level, increased oxidative metabolism in low TRAP1-expressing OC cells and tissues enhanced
production of inflammatory mediators such as interleukin (IL)-6 and IL-8. Mechanistically, we identified members of the multidrug
resistance complex (MDR) as key mediators of such metabolism-driven, inflammation-induced process. Indeed, treatment of OC
cell lines with TNFα and IL6 induced a selective increase in the expression of TAP1 and multidrug resistance protein 1, whereas
TAP1 silencing sensitized cells to cisplatin-induced apoptosis. Our results unveil a novel role for TRAP1 and oxidative metabolism
in cancer progression and suggest the targeting of mitochondrial bioenergetics to increase cisplatin efficacy in human OC.
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The current paradigmatic view, based on the classic observa-
tions of Otto Warburg, recognizes tumour cells as defective
in mitochondrial respiration and mostly relying on glycolytic
metabolism. However, very recent observations provide
opposite evidence showing that melanoma cells are
critically dependent on oxidative phosphorylation (OXPHOS)
rather than glycolysis1,2 and that respiratory function is
essential for tumorigenic and metastatic potential of breast
cancer andmelanoma cells.3,4 Notably, it has been shown that
the most aggressive ovarian cancer (OC) cell lines show a
marked dependence on glutamine rather than on glucose,5
and cancer stem cells from epithelial OC (EOC) patients
privilege OXPHOS and resist glucose deprivation,6 suggest-
ing that glycolysis is not the main pathway sustaining
tumour growth in these systems. EOC is the fifth most
common malignancy in women worldwide and, as the
introduction of platinum-based chemotherapy, only modest
increases in overall survival have been registered.7 Indeed,
EOC is considered a chemo-responsive neoplasm, but,
despite this, the majority of patients ultimately develop
recurrent disease, with over 60% of women eventually dying
from their disease within 5 years of diagnosis.7 In this context,
the identification of reliable biomarkers that would allow to
tailor treatment according to the patient’s disease is urgently
needed. Interestingly, high expression of the tumour necrosis
factor receptor-associated protein 1 (TRAP1) has been
often proposed as a biomarker predictive for poor outcome,
among others, in colorectal,8 hepatocellular,9 non-small cell
lung10 and prostate11 carcinomas. Moreover, TRAP1 has
been recognized as a positive regulator of expression12 and
activity13 of the oncogene BRAF, as a factor favouring
resistance to taxanes14 and anthracyclins15 in breast cancer
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and a regulator of cell migration and tumour metastases.16,17
However, whether TRAP1 roles in tumour development and
progression are generally oncogenic or not is still a matter of
debate. Recently, it has been reported an inverse correlation
between TRAP1 expression and tumour stage in cervical,
bladder and clear cell renal cell carcinoma.18 Among them,
remarkably, cervical carcinoma relies mostly on OXPHOS for
its energetic metabolism.19 This is of particular interest,
because TRAP1 is an important determinant of tumour
metabolism20 and has been proposed as a pivotal driver of
cancer cell’s shift fromOXPHOS toward aerobic glycolysis, the
so-called Warburg effect.21 Interestingly, recent data also
directly correlate TRAP1 expression and overall survival
of OC patients.22 Altogether, these observations prompt us
to raise the hypothesis that TRAP1-dependent regulation
of cellular metabolism and its role in cancer development/
progression could be mutually related. Herein, we demon-
strate that TRAP1 expression and the consequent metabolic
rewiring control platinum resistance and tumour progression
through an inflammation-mediated mechanism. By addres-
sing several open questions in human OC, this study
could provide relevant knowledge for novel therapeutic
approaches based on the targeting of mitochondrial bioener-
getics to improve drug efficacy in tumours with increased
oxidative metabolism.
Results
TRAP1 expression associates with OC progression and
survival. Preliminary analyses in a subset of OC tissues
indicated that high TRAP1 expression has a positive impact
on chemotherapy response and overall survival,22 oppositely
to what well demonstrated in colorectal, prostate and many
other cancers.23 To shed further light on TRAP1 functions in
OC, we took advantage of publicly available serous ovarian
cancer cases from Tothill dataset. We used gene expression
microarray data (263 samples) to perform correlation
analyses between TRAP1 expression and tumour stage,
grade and survival. Surprisingly, data showed that lower
TRAP1 expression is associated with more advanced
disease in OC samples (Figure 1); more specifically, TRAP1
expression has an inverse tendency with tumour stage
(N=263, P=0.0631) (Figure 1a), a significant inverse
correlation with grade (N=260, P=0.007699) (Figure 1b),
and it is associated with better progression-free surviree
survival (PFS) (Figure 1c) (N= 255, P=0.0116), this also
suggesting that higher TRAP1 expression associates with
better chemotherapy response. A significant separation of
PFS curve before 50 months is clinically relevant, considering
that the median PFS for high grade serous OC (HGSOC)
patients is 15 months. These findings confirm an intriguing
role for TRAP1 in OC progression and outcome.
Figure 1 Lower TRAP1 expression is associated with more advanced disease. (a) Correlation between TRAP1 mRNA expression and tumour stage from the Tothill data set
(P-values determined by the Kruskal–Wallis test). (b) Correlation between TRAP1 mRNA expression and tumour grade from the Tothill data set (P-values determined by the
Wilcoxon rank sum test). (c) Kaplan–Meier estimates of the impact of TRAP1 on PFS (P-values determined by the log-rank test). (d) Total lysates obtained from PEA1-sensitive
and PEA2-resistant cells were separated by SDS-PAGE and immunoblotted with the indicated antibodies. Images are representative of three independent experiments. (e) Real-
time RT-PCR analysis of TRAP1 mRNAs expression in PEA1-sensitive and PEA2-resistant cells. Data are expressed as mean± S.E.M. from three independent experiments with
technical triplicates each. Numbers above bars indicate the statistical significance (P-value), based on the two-tailed Student’s t-test
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To further characterize TRAP1 relevance in OC biology, we
used as a model two OC matched cell lines obtained from the
same patient with HGSOC before and after development of
clinical platinum resistance (PEA1/PEA2).24 We analyzed
TRAP1 expression levels in both cell lines and, in agreement
with our patients’ survival analysis, we found that platinum-
resistant OC PEA2 cells show lower TRAP1 expression levels
than their sensitive counterpart PEA1, both at protein and
mRNA levels (Figures 1d and e).
Low TRAP1 expression correlates with oxidative meta-
bolism. Data from public gene expression databases display
that TRAP1 expression inversely correlates with tumour
stage in cervical cancer,18 that, interestingly, has been
shown to prevalently rely on OXPHOS for its energy
metabolism,19 whereas TRAP1 is an important driver of
glycolytic metabolism.21 Therefore, we hypothesized that
TRAP1 could act as a tumour suppressor in a context in
which OXPHOS is the preferential pathway for ATP source.
To this aim, metabolic features of OC cells were investigated
by the BioEnergetic Cellular (BEC) index calculation,
obtained through densitometric analysis of the ratio between
F1ATPase, HSP60 and GAPDH expression levels: a higher
BEC index correlates with an increased dependence on
respiratory capacity. The BEC index has been exploited as
prognostic value in several cancer types, including OC.25 We
found that the BEC index is significantly increased upon
siRNA-mediated TRAP1 silencing in PEA1 and also tend to
increase in PEA2 cells, indicating a bioenergetic shift toward
OXPHOS, and analogous results were obtained in sh-
mediated stable TRAP1 silencing in PEA1 cells (Figure 2a).
Moreover, the same analysis indicates for PEA2 cells a
BEC index value higher than their sensitive counterpart
PEA1, which correlates with TRAP1 expression levels,
thus suggesting a predominant oxidative metabolism in
chemoresistant cells (Figure 2a) and supporting TRAP1 role
in downregulation of mitochondrial activity.
To verify the relevance of TRAP1 and metabolism roles in
patients, we analyzed 47 HGSOC tissue specimens for
TRAP1 expression and for BEC index markers by WB.
Remarkably, a positive and statistically significant correlation
was found between tumour grade and BEC index (Figure 2b),
whereas high TRAP1 protein expression correlated with better
overall survival in the same patients (Figure 2c). These data
support the in vivo relevance of our findings in human
pathology, and indicate that in more aggressive tumours
TRAP1 expression decreases and BEC index increases,
suggesting altogether a shift toward OXPHOS metabolism in
advanced OC.
TRAP1 is responsible for a metabolic shift in OC cells. To
further validate TRAP1 role in OC bioenergetics, we
performed metabolic analyses in our paired cell lines. The
extracellular acidification rate (ECAR), an indicator of glyco-
lysis, and oxygen consumption rate (OCR) were measured
using the Seahorse XFe96 Bioanalyzer (North Billerica, MA,
USA). First, PEA1 and PEA2 bioenergetics was analyzed to
understand whether low TRAP1 background in chemoresis-
tant cells is correlated to a metabolic shift toward OXPHOS.
ECAR analysis shows a higher glycolytic capacity (either
basal or maximal) in PEA1 compared with PEA2 (Figure 3a);
furthermore, OCR value is significantly higher in PEA2 cells
compared with PEA1 cells (Figure 3b), thus indicating again
that chemoresistant cells, with low TRAP1 levels, shifted more
toward mitochondrial function for ATP production. To further
support the impact of TRAP1 expression on OC cells’
bioenergetics, the same Seahorse analysis was performed
on PEA1 cells upon siRNA-mediated TRAP1 silencing.
Results show that TRAP1 silencing does not affect glycolytic
activity (Figure 3c), whereas both basal and maximum OCR
are significantly increased (Figure 3d). These results confirm
Figure 2 Drug resistance and tumour grade are associated with cell metabolism in OC. (a) BEC index analysis on PEA1 and PEA2 cells upon TRAP1 silencing. Where
indicated, cells were transfected with TRAP1-directed or control siRNAs; 72 h after transfection, cells were harvested and total protein lysates were immunoblotted with anti-
βF1ATPase, anti-HSP60 and anti-GAPDH antibodies. Immunoreactive bands were quantified by using ImageJ and BEC index was calculated by the formula F1ATPase/HSP60/
GAPDH (see Material and Methods section for details). Data are expressed as mean±S.E.M. from five independent experiments. Numbers above bars indicate the statistical
significance (P-value), based on the two-tailed Student’s t-test. (b) Total lysates obtained by a set of OC tissues (n= 47) were analyzed by WB analysis for BEC index calculation
as described in panel (a). The resulting BEC index values were normalized on a reference sample and correlated to clinical parameters of each sample. (c) Kaplan–Meier
estimates of the impact of TRAP1 on Overall Survival (P-values determined by the log-rank test)
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our BEC index data, showing a shift toward OXPHOS in
PEA1 cells upon TRAP1 silencing and in PEA2 chemoresis-
tant cells, further supporting the previously described role of
TRAP1 as a modulator of mitochondrial metabolism.20
On the basis of these observations, we aimed at verifying
whether the metabolic features related to TRAP1 expression
were accompanied by a change in expression or activity of key
glycolytic enzymes, namely GAPDH and PFK. We then
assessed the expression levels of these proteins by WB,
comparing PEA1 and PEA2 cells and TRAP1-silenced
PEA1 cells. GAPDH and PFK expression levels are
decreased in PEA2-resistant cells compared with PEA1-
sensitive cells (Figure 4a), in keeping with impairment of
glycolysis observed by Seahorse analysis in these cells.
Conversely, TRAP1 silencing in PEA1 does not modify
expression levels of such genes (Figure 4b), neither affects
Figure 3 Modulation of TRAP1 expression causes metabolic shift in OC cells. (a and b) Kinetic profile of ECAR and OCR in PEA1 and PEA2 cells was measured in real-time,
under basal conditions and in response to glucose, oligomycin and 2-DG for ECAR (panel a), and in response to mitochondrial drugs oligomycin, FCCP, Antimycin A and
Rotenone for OCR (panel b). Indices of glycolytic pathway activation, calculated from PEA1 and PEA2 cells ECAR profile: basal ECAR, maximal ECAR and glycolytic capacity
(see also Materials and Methods section). Indices of mitochondrial respiratory function, calculated from PEA1 and PEA2 cells OCR profile: basal OCR, ATP-linked OCR and
maximal OCR (see also Materials and Methods section). For each profile is shown one representative out of three independent experiments. Data are expressed as
mean± S.E.M. of three measurements, each of them in triplicates. (c and d) Kinetic profile of ECAR and OCR in PEA1 cells transfected with non-targeted control siRNA or
TRAP1-directed siRNA was measured as described for PEA1 and PEA2 cells. For each profile, one representative out of three independent experiments is shown. Data are
expressed as mean± S.E.M. of three measurements, each of them in triplicates. (Statistical analysis by two-tailed Mann–Whitney test)
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the activity of PFK, the rate-limiting enzyme of glycolysis, as
demonstrated by colorimetric assays, whereas PFK activity is
strongly decreased in PEA2 in comparison with PEA1 cells
(Figure 4c). These data further confirm the metabolic profile
obtained by Seahorse assays, showing that TRAP1 is directly
involved in the regulation of mitochondrial respiration in these
cells, but not in glycolysis.
The limited dependence of PEA2 cells from glucose
sources is also confirmed by viability assays. PEA1 and
PEA2 cells were grown for 72 h in a low-glucosemedium, then
cell viability was assessed by MTT assay. Results show that
PEA2 cells are more resistant to glucose deprivation than their
sensitive counterparts, thus demonstrating again their inde-
pendence from glycolysis for survival (Figure 4d).
OXPHOS drives cisplatin resistance in low TRAP1 back-
ground. Once demonstrated the role of TRAP1 in OC
metabolic shift, we tested the hypothesis that TRAP1 itself
could be responsible for cisplatin sensitivity through this
metabolic remodelling. Apoptosis was then investigated by
caspase 3/7 activity assays in TRAP1-silenced PEA1 cells
upon cisplatin treatment: as shown in Figure 5a, TRAP1
silencing yields cells more resistant to cisplatin-induced
caspase cleavage. PEA1 sh-TRAP1 stable transfectants
are also more resistant to cisplatin treatment than controls
(Supplementary Figure S1). Interestingly, glucose withdrawal
induces cisplatin resistance in both control and TRAP1-
silenced PEA1 cells, thus suggesting that inhibition of
glycolysis and metabolic shift toward OXPHOS may be
responsible for the response to the drug (Figure 5a).
We then reasoned that, if TRAP1-silenced cells are more
resistant to cisplatin and more addicted to OXPHOS, the
inhibition of mitochondrial respirationmay sensitize these cells
to cisplatin-induced apoptosis. To test our hypothesis, we
combined cisplatin treatment with subtoxic concentrations of
metformin, a well-known antidiabetic drug, which is an inhibitor
of complex I of the respiratory chain.26 Results show that
metformin restores sensitivity to cisplatin in TRAP1-interfered
PEA1 cells (Figure 5b). Accordingly, PEA2-resistant cellswere
resensitized to cisplatin treatment when coupled with metfor-
min, as demonstrated by both viability (Figure 5c) and
caspase activity assays (Figure 5d). Interestingly, antineo-
plastic effects of metformin have been recently reported in OC
models.27 These results were further confirmed by viability
Figure 4 Glycolysis is decreased in resistant cells but not affected by TRAP1. (a and b) Total lysates obtained from PEA1-sensitive and PEA2-resistant cells (a) or from
PEA1 cells transfected for 72 h with non-targeted control siRNA or TRAP1-directed siRNA (b), were separated by SDS-PAGE and immunoblotted with the indicated antibodies.
Numbers indicate densitometric band intensities, calculated by assuming protein levels of the control equal 1. Images are representative of three independent experiments.
(c) PFK1 activity was measured by a colorimetric assay in PEA1-sensitive and PEA2-resistant cells and in PEA1 cells transfected for 72 h with non-targeted control siRNA
or TRAP1-directed siRNA. Data are expressed as mean± S.E.M. from three independent experiments with technical triplicates each. Numbers above bars indicate the statistical
significance (P-value), based on the two-tailed Student’s t-test. (d) Viability assays performed by MTT in PEA1 and PEA2 cells cultured in complete medium or in low-glucose
medium for 72 h. Absorbance was measured at 570 nm by subtracting background values at 690 nm. Data are expressed as mean±S.E.M. from four independent experiments
with technical triplicates each. Numbers above bars indicate the statistical significance (P-value), based on the two-tailed Student’s t-test
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assays using, instead of metformin, the ATP synthase inhibitor
oligomycin, which significantly potentiates the effect of
Cisplatin (Supplementary Figure S2). Conversely, we asked
whether cisplatin resistance could be directly induced by
increased OXPHOS activity. To this aim, PEA1 cells were
treated with the uncoupler agent FCCP, which increases
Figure 5 Cisplatin resistance in OC cells is mediated by oxidative metabolism. (a) PEA1 cells were transfected with non-targeted control siRNA or TRAP1-directed siRNA.
Seventy-two hours after transfection, cells were placed in high-glucose (4.5 g/l) or low-glucose (1 g/l) medium and, after 1 h, further treated for 24 h with 20 μM cisplatin.
Subsequently, apoptosis was measured by a luminescent caspase 3/7 activity assay. Data are expressed as mean ± S.E.M. from four independent experiments with technical
triplicates each. (b) PEA1 cells were transfected with non-targeted control siRNA or TRAP1-directed siRNA. Seventy-two hours after transfection, cells were treated for 24 h with
20 μM cisplatin, 10 mMmetformin or both. Subsequently, cell viability was measured by MTTassay. Data are expressed as mean ± S.E.M. from three independent experiments
with technical triplicates each. (c and d) PEA2 cells were treated with 40 μM cisplatin, 10 mM metformin or both for 24 h, then cell viability was measured by MTTassay (c) and
apoptosis was measured by a luminescent caspase 3/7 activity assay (d). See also Supplementary Figure S1. Data are expressed as mean ± S.E.M. from four independent
experiments with technical triplicates each. (e and f) PEA1 cells were treated with 20 μM cisplatin, 1.2 μM FCCP or both for 24 h, then apoptosis was measured by caspase 3/7
activity luminescent assay (e) and their viability was assessed by MTT assay (f). Data are expressed as mean ± S.E.M. from five independent experiments with technical
triplicates each. (g and h) Cells were pretreated for 1 h with NAC 1 mM, then treated with 20 μM (PEA1) or 40 μM cisplatin (PEA2) after NAC washout. After 24 h, cell viability
was measured by MTTassay (g) and apoptosis was measured by a luminescent caspase 3/7 activity assay (h). Data are expressed as mean ± S.E.M. from four (PEA1-PEA2)
or six independent experiments (sh-control and sh-TRAP1 PEA1 cells) with technical triplicates each. In all panels, numbers above bars indicate the statistical significance
(P-value), based on the two-tailed Student’s t-test
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respiration rate without affecting ATP cellular production,
alone or in combination with cisplatin and, as expected, we
demonstrated that FCCP reverts cisplatin apoptotic effect
(Figures 5e and f), thus supporting our idea of a metabolic
involvement in cisplatin resistance of OC systems. Reactive
oxygen species (ROS) production could reasonably lie
between low TRAP1/high OXPHOS and cisplatin resistance.
Indeed, ROS assays demonstrate that platinum-resistant
PEA2 and TRAP1 knock-down PEA1 cells contain higher
ROS levels than their respective counterparts (Supplementary
Figure S3). Furthermore, both viability and apoptosis assays
(Figures 5g and h) show that antioxidant tretament with
N-acetyl cysteine (NAC) sensitizes PEA1 and PEA2 cells, as
well as TRAP1 knock-down PEA1 cells and control, to
cisplatin-induced cell death. Altogether, these data reinforce
the hypothesis that TRAP1 is involved in cisplatin sensitivity
through metabolic remodelling in OC cells.
TRAP1-mediated metabolic shift elicits inflammatory
response. As demonstrated by apoptosis and cell viability
assays, inhibition of glycolysis by glucose deprivation
(Figure 5a) and OXPHOS stimulation by FCCP treatment
(Figures 5e and f) are per se able to induce cisplatin
resistance in PEA1-sensitive cells. These results prompted
us to search for the molecules directly responsible for the
modulation of cisplatin function in these conditions. To this
aim, we cultured PEA1 cells for 6 h in the absence of glucose,
and then performed a whole-genome gene expression
analysis as described in Materials and Methods section,
by comparing glucose deprived to control cells. This
approach led to the identification of a set of 2158 (1072
upregulated and 1086 downregulated) regulated genes (see
Supplementary Table S1 for the full list of differentially
regulated genes). The Ingenuity Pathway Analysis (IPA)
software allowed us to identify, among the five most relevant
regulated biofunctions, the aryl hydrocarbon receptor signal-
ling and the glucocorticoid receptor signalling, two pathways
involved in cellular immune response and inflammatory
activation28,29 (Figure 6a). Interestingly, previous literature
reports that OC is characterized by an autocrine production of
interleukins (ILs) and cytokines30 and recent studies associ-
ate metabolic reprogramming to IL signalling,31 which has
been recently involved in cisplatin resistance.32 Starting from
these observations, we selected the 11 most regulated genes
in these two pathways according to Ingenuity software
(Supplementary Table S2) for qPCR validation upon glucose
deprivation, TRAP1 silencing and treatment with FCCP, an
inducer of mitochondrial respiration (Figure 6b). Among the
selected genes, qPCR analysis confirmed CSF2, HSPA1A,
IL6 and SGK1 as significantly regulated upon a short-term
(6 h) glucose deprivation; TRAP1 silencing yielded analo-
gous regulation of CSF2 and IL6, and also resulted in
significant regulation of IL8 and PLAU; similarly, FCCP
treatment modulated the expression of CSF2, IL6 and PLAU
in the same direction as glucose deprivation and TRAP1
silencing. Interestingly, regulation of CSF2 and IL6 was
common to all treatments, thus suggesting a significant
involvement of such genes in the observed phenomena. To
further support these data, we analyzed the correlations
between the genes validated in the gene expression analysis
and TRAP1 levels by bioinformatic analysis of OC tissue
database (see Supplementary Tables S3 and S4 for the full
list of genes/proteins and their correlation coefficient with
TRAP1). Remarkably, 3 of the 11 genes, namely IL6, PLAU,
MAP2K2, significantly correlated with TRAP1 in the OC
RNAseq TCGA data set (Figure 6c): IL6 and PLAU increased
upon TRAP1 silencing, according to our previous analysis
(Figure 6b). Notably, PLAU and TRAP1 have also been
reported to oppositely respond to anti-oestrogen-based
therapy, with PLAU being downregulated by oestrogen, in
contrast to the upregulation of TRAP1,33 which bears an
oestrogen-responsive element in its promoter region.34
These findings strongly suggest that inhibition of glycolysis
and increased oxidative metabolism in PEA1 cells stimulate
the production of proinflammatory molecules, which may be
responsible for cisplatin resistance.
Metabolism-driven inflammation induces platinum
resistance. We hypothesized that the relevance of
TRAP1-related signature in the onset of OC platinum
resistance may be due to its peculiar ability to produce, in
response to increased OXPHOS, proinflammatory cytokines,
such as IL6 and IL8, which are usually secreted by immune
cells.35 To investigate this hypothesis, we performed a
pathway analysis on the microarray profile of matched cell
lines PEA1/PEA2, PEO1/PEO4/PEO6, PEO14/PEO23.36
Results showed that the inflammatory pathway and the
activation of IL signalling are the most significant differentially
regulated pathways between resistant/sensitive cell lines
(Figure 7a).
As IL6, among all interleukins, resulted upregulated in all
our tested conditions (glucose deprivation, FCCP treatment,
TRAP1 silencing), and inversely correlated to TRAP1 in
human OC samples, we tested whether treatment with human
recombinant IL6 was sufficient to induce resistance to cisplatin
in sensitive cells. To this aim, PEA1 cells were treated with
200 U/ml IL6 4 h before cisplatin addition (20 μM) for further
24 h. Results showed that indeed PEA1 cells became more
resistant to drug treatment, as demonstrated by reduced
apoptosis sensitivity upon IL6 pretreatment (Figure 7b). To
characterize at a molecular level the mechanisms/factors
responsible for this phenomenon, we started from the recent
whole-genome characterization of chemoresistant OC,37
showing that acquired resistance associated with overexpres-
sion of the multidrug resistance protein 1 (MDR1). Therefore,
we focused on two members of this family: ABCB1/MDR1, an
ATP-dependent efflux transporter, whose involvement in
tumour drug resistance has been widely reported,38 and
ABCB2/TAP1, which enhances pancreatic ductal adenocarci-
noma drug resistance39 and, notably, resulted upregulated in
all sets of PEA2/PEO4/PEO23 resistant cells in comparison
with their matched sensitive counterparts.36 To this aim, we
analyzedMDR1 and TAP1 levels by qPCR in PEA1 cells upon
TRAP1 silencing and upon treatment with two different
proinflammatory inducers, namely TNFα and IL6. As shown
in Figure 7c, both TAP1 and MDR1 were upregulated by
TNFα/IL6 exposure, and a significant induction of TAP1 is
observed upon TRAP1 silencing, thus supporting the role of
TRAP1/MDR1-TAP1 pathway in our studymodel. Accordingly,
siRNA-mediated TAP1 silencing yielded an increased
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sensitivity to cisplatin-induced apoptosis in PEA1 cells and
slightly but significantly restored sensitivity to cisplatin in PEA2
cisplatin-resistant cells (Figure7d). Mechanistically, all these
findings allowed us to identify ATP transporters as possible
key proteins involved/responsible for platinum resistance in
these OC cells.
Discussion
HGSOC is the most malignant form of OC and accounts for up
to 70% of all OC cases. Currently, survival rates of patients
with OC remain poor and OC continues to be a poorly
understood disease.40 Indeed, OC experimental models are
mostly unable to recapitulate the human disease, raising
Figure 6 Metabolic remodelling of PEA1 cells elicits inflammatory response. (a) Pathway activity analysis (2000–2014 Ingenuity Systems, Inc.), representing the eight
canonical pathways most differentially regulated in PEA1 cells upon Glucose deprivation (6 h). Orange bars or blue bars predict an increase or decrease in a pathway’s activity,
respectively. Log (P-value) indicates statistical significance of selected pathway, z-score is used to infer the activation states of predicted pathways, and ratio indicates percentage
of genes in analysis compared with the whole pathway gene list (see also Supplementary Table S1). (b) Real-time RT-PCR analysis of expression of 11 selected genes belonging
to the glucocorticoid receptor signalling or the aryl hydrocarbon receptor signalling, following 6 h of glucose deprivation, upon siRNA-mediated TRAP1 silencing, and following 6 h
of FCCP treatment in PEA1 cells (see also Supplementary Table S2). All data are expressed as mean ± S.E.M. from four independent experiments with technical triplicates
each. Numbers above bars indicate the statistical significance (P-value), based on the one-sample t-test. Solid line indicate expression level of the relative control. (c) Correlation
between TRAP1 expression and IL6, MAP2K2 and PLAU mRNA expression in TCGA data set. P-values determined by the Pearson's product moment correlation coefficient.
See also Supplementary Table S3
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debate about the need for better systems.41 Therefore, we
started from a set of HGSOC tissue specimens and confirmed
our data at molecular level taking advantage of multiple set of
matched HGSOC cell lines (PEA1/PEA2, PEO1/PEO4/PEO6,
PEO16/PEO23), derived from the same patient before (PEA1,
PEO1, PEO16) and after (PEA2, PEO4, PEO6, PEO23) the
development of platinum resistance. Moreover, we have
repeatedly matched the obtained results with a large database
of HGSOC biopsies by analyzing the correlation between
expression data in RNA/protein arrays and metabolic and
clinical data of patients, also further confirming all the findings
in 47 HGSOC tissue specimens. As a result, we found that
lower levels of the molecular chaperone TRAP1 are asso-
ciated with advanced disease and poor survival in HGSOC.
This is surprising on the basis of the present literature,
presenting TRAP1 as a component of the HSP90 mitochon-
drial survival pathway with antioxidant42 and antiapoptotic
functions,43 and a very promising prospective target for novel
cancer therapeutics.44 Recent advances in TRAP1 biology
have shown that it functions as a network hub protein, involved
Figure 7 Activation of inflammatory pathways is responsible for cisplatin resistance. (a) Pathway activity analysis (2000–2014 Ingenuity Systems, Inc.), representing the eight
canonical pathways most differentially regulated in PEA2/PEO4/PEO23 resistant cells in comparison with their matched sensitive counterparts. Orange bars or blue bars predict
an increase or decrease in a pathway’s activity, respectively. Log (P-value) indicates statistical significance of selected pathway, z-score is used to infer the activation states of
predicted pathways, and ratio indicates percentage of genes in analysis compared with the whole pathway gene list. (b) PEA1 cells were treated with 20 μM cisplatin in the
presence/absence of human IL6 (200 U/ml) for 24 h, then apoptosis was measured by caspase 3/7 activity luminescent assay. Data are expressed as mean± S.E.M. from four
independent experiments with technical triplicates each. Numbers above bars indicate the statistical significance (P-value), based on the two-tailed Student’s t-test. (c) Real-time
RT-PCR analysis of MDR1 and TAP1 expression in PEA1 cells 72 h after transfection with non-targeted control siRNA or TRAP1-directed siRNA or after 6-h treatment with human
IL6 (200 U/ml) or both TNFα (20 ng/ml) and IL6. Data are expressed as mean±S.E.M. from three independent experiments with technical triplicates each. Numbers above bars
indicate the statistical significance (P-value), based on one-sample t-test. Solid line indicate expression level of the relative control. (d) PEA1 and PEA2 cells were transfected with
non-targeted control siRNA or TAP1-directed siRNA. Seventy-two hours, cells were treated for 24 h with 20 μM cisplatin (PEA1) or 40 μM cisplatin (PEA2). Subsequently,
apoptosis was measured by a luminescent caspase 3/7 activity assay. Data are expressed as mean± S.E.M. from three independent experiments with technical triplicates each.
Numbers above bars indicate the statistical significance (P-value), based on the two-tailed Student’s t-test
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in most cellular processes responsible for the rewiring
of tumour metabolism, including the regulation of protein
synthesis and degradation,45,46 endoplasmic reticulum
stress protection of cancer cells47,48 and the regulation of
mitochondrial physiology and cancer cell metabolism.21 This
apparent contradiction is unravelled by the observation that
higher oxidative metabolism correlated with higher tumour
grade in OC, and that cisplatin-resistant OC cells showed
lower TRAP1 levels and increased OXPHOS and ROS
levels. Accordingly, TRAP1 silencing in cisplatin-sensitive
cells increased OCR/ROS, induced cisplatin resistance and,
strikingly, this phenotype was reversible upon pharmacologi-
cal inhibition of mitochondrial OXPHOS or ROS scavenging.
For decades, decreased capacity for OXPHOS because of
dysfunctional mitochondria and increased glycolysis have
been considered as dominant in neoplastic cells; however,
very recent observations challenge this view in a growing
number of tumour systems, especially melanoma.49 Remark-
ably, recent data suggested that OC could be included in the
list, showing that the most aggressive OC cell lines mostly
depend on glutamine rather than on glucose5 and cancer stem
cells from EOC patients privilege OXPHOS and resist glucose
deprivation.6 Intriguingly, the first inverse correlations between
TRAP1 and tumour stage was reported in bladder, clear cell
renal cell and cervical carcinoma,18 with the latter mostly
relying on OXPHOS for its energetic metabolism.19 In
agreement, previous data correlated TRAP1 expression with
favourable chemotherapy response and overall survival in a
subset of ERα-positive OC patients.22
Our results show that the strict correlation between low
TRAP1 expression and oxidative metabolism in OC cells is
responsible for progression of disease and response to
platinum-based therapy, through the activation of an inflam-
matory programme. Proinflammatory cytokines, such as IL6,
are usually secreted by immune cells, but their expression has
been documented in osteosarcomas,50 OC cells35 and head
and neck squamous cell carcinoma cells.51 Some interesting
observations show that elevated levels of IL6 in the sera and
ascites of OC patients predict poor clinical outcome,52 IL8 and
IL8 receptor have been proposed as potential prognostic
biomarkers and therapeutic targets53 and have a role in
platinum response in HGSOC.32 However, to our knowledge,
no connection has ever been demonstrated between inflam-
mation, metabolism and drug resistance. In this regard,
a very recent work shows that loss of p62 (a NF-κB regulator)
in stromal fibroblasts of prostate cancer promoted tumour
progression through a regulation of cellular redox,
resulting in increased IL6 production.31 A model for the
OXPHOS-mediated activation of survival pathways in
the establishment of platinum resistance in OC is shown
in Figure 8. Mechanistically, we identified MDR subfamily
members (TAP1 and MDR1) as key mediators of such
metabolism-driven, inflammation-induced drug resistance.
Consistently, according to a recent whole-genome character-
ization of chemoresistant OC,37 acquired resistance asso-
ciated with overexpression of the drug efflux pump MDR1. It
has been proposed that platinum-resistant HGSOC clones
may arise from low-abundance subset of cells within the
sensitive tumour through a selection process, rather than
Figure 8 A model for the OXPHOS-mediated activation of survival pathways in low versus high TRAP1-expressing ovarian tumour cells following clinically acquired platinum
resistance. Cells expressing low TRAP1 levels have increased OXPHOS activity, which is usually escaped by cancer cells in order to pursue the advantages of aerobic glycolysis.
However, OC is characterized by an autocrine production of ILs and cytokines, mainly produced by immune cells, whose expression is stimulated by OXPHOS through an
unknown mechanism. This elicits an inflammatory response, which is responsible for resistance to cisplatin
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through adaptation.54 Metabolic characterization of similar
sub-populations of tumorigenic and multidrug resistant cells in
other cancer types revealed their dependency on mitochon-
drial respiration,49 which is consistent with our data.
In this regard, the antidiabetic metformin, is already under
investigation for possible applications in oncology55 and has
been recently reported as an effective antineoplastic agent in
OC models.27 In conclusion, we suggest that metabolic
features of tumour cells in the peculiar environment of OC
can predict cisplatin sensitivity and that TRAP1, bioenergetic
index and proinflammatory molecules can serve as predictive/
prognostic biomarkers of therapeutic outcome. In this context,
we propose the targeting of OXPHOS to improve cisplatin
efficacy in tumours with increased oxidative metabolism.
Materials and Methods
Cell cultures. The paired HGSOC cell lines PEA1 and PEA2 have been
described elsewhere.24 Cell line verification was by Identifiler kit (Applied Biosystems-
Thermo Fisher Scientific, Waltham, MA, USA). TRAP1 stable interfered cells were
obtained by transfecting PEA1 cells with TRAP1 (5'-TGCTGTTGACAGTGAGC
GACCCGGTCCCTGTACTCAGAAATAGTGAAGCCACAGATGTATTTCTGAGTACAGG
GACCGGGCTGCCTACTGCCTCGGA-3') or scrambled (sequence containing no
homology to known mammalian genes) short hairpin RNAs (Open Biosystem,
Dharmacon, Arese, Italy) and isolating positive clones by selection with Puromycin
(Sigma-Aldrich, Milano, Italy) 1 μg/ml. All lines were maintained in RPMI-1640 media
with 10% foetal bovine serum, penicillin, streptomycin, glutamine at 37 °C/5% CO2.
Cell lines are routinely monitored in our laboratory by microscopic morphology check.
Transfection procedures. TRAP1 transient silencing was performed with
siRNAs purchased from Qiagen (cat. no. SI00115150); sense strand: 5'-CGGUCC
CUGUACUCAGAAATT-3'; antisense strand: 5'-UUUCUGAGUACAGGGACCGG
G-3'. For control experiments, cells were transfected with a similar amount of
nontargetin control siRNA (Qiagen, Milano, Italy; cat. no. SI03650318). Transient
transfections of siRNAs were performed using HiPerFect Transfection Reagent
(Qiagen) according to the manufacturer's protocol.
Tumour lysates. Tumour samples were manually cut in ice cold T-PER Lysis
Buffer (Thermo Scientific, Waltham, MA, USA) and sonicated. Samples were
centrifuged twice at 10 000 × g for 10 min at 4 °C and supernatants were collected
and quantified.
Western blot analysis. Equal amounts of protein from cell lysates and
tumour specimens were subjected to SDS-PAGE and transferred to a PVDF
membrane (Merck-Millipore, Darmstadt, Germany). Where indicated, protein levels
were quantified by densitometric analysis using the software ImageJ.56 The
following antibodies were used: anti-TRAP1 (sc-13557), anti-β-actin (sc-69879),
anti-GAPDH (sc-69778), anti-ATP5B (sc-16690), anti-HSP60 (sc-1052), from Santa
Cruz Biotechnology (Dallas, TX, USA); anti-PFK1 (NBP2-32170) from Novus Bio
(Abingdon, UK).
RNA extraction and real-time RT-PCR. Total RNA extraction procedures
were performed by using TRI Reagent (Sigma-Aldrich, product code T9424),
following the manufacturer’s instruction. The following primers were used for PCR
analysis. TRAP1: forward 5'-GACGCACCGCTCAACAT-3', reverse 5'-CACATCAAA
CATGGACGGTTT-3'; ACTIN: forward 5'-CCTCACCCTGAAGTACCCCA-3', reverse
5'-TCGTCCCAGTTGGTGACGAT-3'; IL8: forward 5′-CCAGTCTTGTCATTGCCAGC
-3′, reverse 5′-TGACTGTGGAGTTTTGGCTGT-3′; IL6: forward 5′-TGCAAT;AAC
CACCCCTGACC-3′, reverse 5′-CAATCTGAGGTGCCCATGCT-3′; CSF2: forward
5′-GTCATCTTGGAGGGACCAAGG-3′, reverse 5′-CCATGCCTGTATCAGGGTCA
G-3′; HSPA1A: forward 5′-GGGCCTTTCCAAGATTGCTG-3′, reverse 5′-TGCAAAC
ACAGGAAATTGAGAACT-3′; CCND1: forward 5′-TGCTGCGAAGTGGAAACCAT
C-3′, reverse 5′-CACTTCTGTTCCTCGCAGAC-3′; PLAU: forward 5′-CTGTGTGG
ACTGTGATGCCA-3′, reverse 5′-CAGTGCTGGTCACAGGTCAT-3′; CCNA2: forward
5′-ACACAGTCACGGGACAAAGC-3′, reverse 5′-TGCTGTGGTGCTTTGAGGTA-3′;
SGK1: forward 5′-CGTTAGAGTGCCGCCTTAGA-3′, reverse 5′-TTCGTCATCACA
GCCCAGAC-3′; MAP2K2: forward 5′-CGGACCTGAAGATGCTCACA-3′, reverse
5′-TTCAGCCGCAGGGTTTTACA-3′; HSPA14: forward 5′-GGGTGTGGACGAATCA
GGAG-3′, reverse 5′-ATATGCTTCCAGGGGCTTGC-3′; PCK2: forward 5′-CCCCAA
GGACTTCTGGGAAC-3′, reverse 5′-TTGGGCAGATCCTGGTTGAC-3′; MDR1:
forward 5’-TCCTCAGTCAAGTTCAGAGTCTTCA-3’, reverse 5’-TCTCCACTTGATG
ATGTCTCTCACT-3’; TAP1: forward 5’-CCTCCTTTCCAAGCTCCTCG-3’, reverse
5’-GGCCAGCATATGCCTTCAGT-3’. When possible, primers were designed to be
intron spanning. The reaction conditions were 95 °C for 5 min followed by 45 cycles
of 15 s at 95 °C and 1 min at 60 °C. Actin was chosen as the internal control.
In PCR analyses performed upon TRAP1 silencing, RNAs were collected 72 h after
siRNA transfection; in PCR analyses performed upon FCCP treatment and glucose
deprivation, RNAs were collected after 6-h treatment.
Metabolic analyses. The BEC indices of the cell lines and tissue samples
were calculated, based on digital density scanning of western blots as described
above, by dividing the ratio of βF1ATPase to HSP60 with the GAPDH value.
The metabolic profile has been evaluated in PEA1, PEA2 cell lines and in
PEA1 cells silenced for TRAP1 (72 h after transfection). Real-time measurements of
OCR and ECAR were made using an XF-96 Extracellular Flux Analyzer (Seahorse
Bioscience, North Billerica, MA, USA). Cells were plated in XF-96 plates (Seahorse
Bioscience) at the concentration of 4 × 104 cells per well and cultured for 12 h in
DMEM medium supplemented with 5% FBS. OCR was measured in XF media
(non-buffered DMEM medium, containing 10 mM glucose, 2 mM L-glutamine and
1 mM sodium pyruvate), under basal conditions and in response to 2.5 μM
oligomycin, 1.5 μM of carbonylcyanide-4-(trifluoromethoxy)-phenylhydrazone
(FCCP) and 1 μM of Antimycin and Rotenone (all from Sigma-Aldrich). Indices of
mitochondrial respiratory function were calculated from OCR profile: basal OCR
(before addition of oligomycin), ATP-linked OCR (calculated as the difference
between basal OCR rate and oligomycin-induced OCR rate) and maximal OCR
(calculated as the difference of FCCP rate and antimycin+rotenone rate). ECAR was
measured in XF media in basal condition and in response to 10 mM glucose, 2.5 μM
oligomycin and 100 mM of 2-DG (all from Sigma-Aldrich). Indices of glycolytic
pathway activation were calculated from ECAR profile: basal ECAR (after the addition
of glucose), maximal ECAR (after the addition of oligomycin) and glycolytic capacity
(calculated as the difference of oligomycin-induced ECAR and 2-DG-induced ECAR).
Experiments with the Seahorse system have been performed with the following assay
conditions: 3-min mixture; 3-min wait; and 3-min measurement; metabolic parameters
were then calculated. Data are expressed as mean±S.E.M.
PFK activity was assessed by using Phosphofructokinase Activity Colorimetric
Assay Kit (Sigma, product code MAK093), following the manufacturer's instructions.
When assessing PFK activity upon TRAP1 silencing, the assay was performed 72 h
after siRNA transfection.
Detection of intracellular ROS in live cells was performed by using the Fluorometric
Intracellular Ros Kit (MAK145, Sigma), according to the manufacturer’s instructions.
Cell treatments and apoptosis and viability assays. In glucose
deprivation experiments, cells were plated in monolayer in complete medium. After
seeding, medium was replaced with a low-glucose (1 g/l) RPMI medium (Sigma). In
cell viability and apoptosis assays, PEA1 cells were treated with 20 μM cisplatin for
24 h, whereas PEA2 cells were treated with 40 μM cisplatin for 24 h. In sensitization
experiments, cells were treated for 24 h with metformin 10 mM, or contemporary
with metformin and cisplatin for 24 h, with the same concentrations indicated above.
In acquired resistance experiments, cell were pretreated with FCCP 1.2 μM or with
human IL6 200 U/ml for 4 h, before adding cisplatin for further 24 h.
Cell viability was measured by MTTassay by using the In vitro toxicology assay kit
(Sigma, product code TOX1-1KT), following the manufacturer's instructions.
Apoptosis was measured using the Caspase-Glo 3/7 assay (Promega, Milano, Italy,
product code G8090) and was performed according to the manufacturer's
instructions.
Gene expression analysis. Gene expression analysis (sample preparation,
hybridization, staining, scanning and data preprocessing/quantile normalization)
were performed as described in Condelli et al.12 Differently expressed genes
(DEGs) between cells cultured in low- and high-glucose medium for 6 h were
selected with differential score (DiffScore) cutoff set at ± 13 (Po0.05) and genes
with log fold change ≤−0.3 or ≥ 0.3 were further analyzed. Microarray data were
submitted to Array Express under accession number E-MTAB-3799. The DEGs list
(composed by 909 genes, 462 upregulated and 447 downregulated) was used to
evaluate the functional behaviour in terms of Biological Processes and Canonical
Pathway performing an enrichment analysis with IPA.
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Furthermore, we confirmed all the results, by previous gene expression data36
of multiple sensitive/resistant matched cell lines (PEA1/PEA2, PEO1/PEO4/PEO6,
PEO16/PEO23) derived from the same patient before and after the development
of platinum resistance. Data were extracted from Supplementary Table and Canonical
Pathway of differentially expressed genes were evaluated with IPA.
Statistics. Serous OC cases from Tothill data set (Affymetrix, Santa Clara, CA,
USA U133 plus2.0 microarray, GSE9891) and TCGA data set (level 3 data, total
RNA sequencing and Reverse Phase Protein Array) were used to correlate TRAP1
mRNA expression with stage, grade and PFS in Figures 1a–c, and to correlate with
the expression of other genes in Figure 6c. Wilcoxon rank sum test was used to
compare gene expression between two groups. Kruskal–Wallis test with 10 000
permutation was used to compare gene expression among more than two groups.
Log-rank test was used to determine the significance of the survival analysis.
Pearson's product moment correlation coefficient was used to correlate the mRNA
expression of two genes.
The paired Student’s t-test was used to establish the statistical significance of
differences between gene expression levels in qPCR and between viability/apoptosis/
PFK activity levels under TRAP1 silencing or drug treatments. Two-tailed Mann–
Whitney test was used to determine statistical significance of metabolic
measurements reported in Figure 3.
Patients and study approval. Patients’ samples were collected under the
Imperial College London Tissue Bank project number R15024 (TRAP1 regulates
bioenergetics features, cisplatin resistance and epithelial-mesenchymal transition in
OC) in accordance with the Imperial College London guidelines. Express written
informed consent to use biological specimens for investigational procedures was
obtained from all patients. All experimental protocols were approved by
Hammersmith and Queen Charlotte’s and Chelsea Research Ethics Committee.
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